Phase 2 DNA Clinical Trials

16 recruitingPhase 2

What is a Phase 2 trial?

Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.

Showing 116 of 16 trials

Recruiting
Phase 2

Thinking Zinc: a Study of Zinc Supplements on the Navajo Nation

Immune System DisorderDNA Damage
University of New Mexico100 enrolled1 locationNCT03908736
Recruiting
Phase 2

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Colorectal, CancerMinimal Residual DiseasectDNA+3 more
M.D. Anderson Cancer Center20 enrolled1 locationNCT07136077
Recruiting
Phase 2

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Breast CancerTriple-Negative Breast CancerCirculating Tumor DNA+1 more
Dana-Farber Cancer Institute40 enrolled7 locationsNCT04434040
Recruiting
Phase 2

Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer

Colorectal, CancerChemotherapyctDNA
Fudan University340 enrolled1 locationNCT07562503
Recruiting
Phase 2

A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer

Colorectal, CancerChemotherapyctDNA
Fudan University100 enrolled1 locationNCT07562490
Recruiting
Phase 2

Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer

ctDNAColorectal Cancer (CRC)Adjuvant Chemotherapy
Fudan University80 enrolled1 locationNCT07562659
Recruiting
Phase 2

Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer

Colorectal, CancerChemotherapyctDNA
Fudan University340 enrolled1 locationNCT07562711
Recruiting
Phase 1Phase 2

EBV-AST Cell Therapy for EBV-Related Diseases After Stem Cell Transplantation

Post-Transplant Lymphoproliferative DisorderEBV-DNA Viremia
Daihong Liu18 enrolled1 locationNCT07438067
Recruiting
Phase 2

ctDNA-guided Treatment Decision-making

Metastatic Breast Cancer ( HER2 Negative)ctDNA
Fudan University122 enrolled1 locationNCT07394218
Recruiting
Phase 2

ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer

HER2-negative Breast CancerBreast Cancer Early Stage Breast Cancer (Stage 1-3)Hormone Receptor-Positive Breast Cancer+3 more
Peking University People's Hospital393 enrolled1 locationNCT06970912
Recruiting
Phase 2

Using ctDNA to Determine Therapies for Lung Cancer

Non-small Cell Lung CancerCirculating Tumor DNAComplete Surgical Resection
University Health Network, Toronto66 enrolled1 locationNCT04966663
Recruiting
Phase 2

Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures

Dyskeratosis CongenitaFanconi AnemiaBone Marrow Failure+7 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins27 enrolled1 locationNCT04232085
Recruiting
Phase 2

Deoxynucleosides Pyrimidines as Treatment for Mitochondrial Depletion Syndrome

Mitochondrial DiseasesMitochondrial Metabolism DisordersMitochondrial Encephalomyopathy+2 more
Kenneth Myers, MD200 enrolled1 locationNCT04802707
Recruiting
Phase 2

Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy

Biliary Tract CancerDNA Damage Repair Deficiency
Asan Medical Center62 enrolled1 locationNCT05222971
Recruiting
Phase 2

Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer

Circulating Tumor DNALocally Advanced Rectal Carcinoma
Peking Union Medical College Hospital470 enrolled1 locationNCT05601505
Recruiting
Phase 2

Nutritional polypill trial in well subjects in order to assess genome damage

Damage in lymphocyte deoxyribonucleic acid (DNA)
NHMRC250 enrolled1 locationACTRN12607000651482